ResMed (NYSE:RMD) Upgraded by StockNews.com to “Buy” Rating
ResMed (NYSE:RMD – Get Free Report) was upgraded by equities researchers at StockNews.com from a “hold” rating to a “buy” rating in a research note issued on Friday. Several other equities research analysts have also commented on the stock. The Goldman Sachs Group initiated coverage on shares of ResMed in a research note on Thursday, […]
